Researchers working on an incurable blood cancer can now use a new lab model that could make testing potential new treatments and diagnostics easier and quicker, new research has found.

Researchers have traced where and when the HIV protective mutation arose but also how it gave northern European ancestors a competitive advantage against ancient diseasesA genetic mutation in a ...

Those with the genetic mutation have what is called a “32-bp deletion,” which means the gene known as chemokine receptor 5, or CCR5, isn’t fully expressed, according to the study.

Those with the genetic mutation have what is called a “32-bp deletion,” which means the gene known as chemokine receptor 5, or CCR5, isn’t fully expressed, according to the study.

Those with the genetic mutation have what is called a “32-bp deletion,” which means the gene known as chemokine receptor 5, or CCR5, isn’t fully expressed, according to the study.

Those with the genetic mutation have what is called a “32-bp deletion,” which means the gene known as chemokine receptor 5, or CCR5, isn’t fully expressed, according to the study.